Category: Financing

HBM Pharma/Biotech M&A and New Drug Approvals Reports 
Posted on Mar 15, 2016

  We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms

The Age of Virtual Pharma: Creative Financing and Exit Models 
Posted on Feb 22, 2016

  At last month’s Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It was an interesting discussion because each speaker detailed their own experience in advancing assets without partnering. Examples include risk sharing relationships with CROs and investors. A few

As Scarce As… 
Posted on Sep 23, 2014

Twenty Five. That’s it. What are we talking about? Some of the data in yesterday’s excellent post by Bruce Booth on Early Stage Venture Scarcity really caught us by surprise. What really caught our eye was this nugget: To address this issue, FLAG Capital Management did a further refinement of “active” investors and shared it with

The Biotech IPO Window: Party Like It’s 1999 
Posted on Aug 02, 2013

    According to Burrill & Company, July had the busiest week of biotech IPO activity ever, continuing a trend of heavy fundraising during 2013 so far: In all, 29 life sciences companies raised a total of $5 billion on U.S. exchanges through the first seven  months of 2013. That compares to 11 companies raising

LLC may be better than C corp 
Posted on Aug 13, 2012

We generally agree with the notion that many early-stage biotechs should be structured as LLCs instead of C corps. This short interview with Attorney Albert L. Sokol highlights one key benefit which we find important: When corporations buy a biotech whole, they typically make offers that primarily reflect the value of the drugs that interest

Venture Financing: Is China the answer? 
Posted on Aug 07, 2012

As we read the continuing bad news regarding venture financing in biotech, we came across this bit of news from the UK: BioCity Nottingham-based CompanDX Limited, the Nottingham Trent University spinout applying novel bio-informatics technology to the issues of personalised medicine, is pleased to announce the raising of 39,600,000 Renminbi (CN¥) for development of products

Slow summer? Hardly 
Posted on Jul 17, 2012

Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the “slow” month of July? Here are a few stories of interest that we’ve spotted: Truvada for HIV Prevention – This is truly a remarkable development in HIV. While the industry struggles to develop

AOL Sells Patents To Microsoft 
Posted on Apr 10, 2012

AOL sells patents to Microsoft. Why? The reasons for AOL selling these patents are pretty clear: Shares of AOL surged as much as 45% Monday, hitting their highest point in nearly 1 1/2 years, because the company pledged to return a “significant portion” of the sale proceeds to shareholders.  Further, Under the agreement announced Monday,

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.